Women patients with small-cell lung cancer using immunotherapy in a real-world cohort achieved long-term survival.

Our study suggested that female ES-SCLC patients treated with immunotherapy tended to achieve a relatively longer survival. The incidence of AEs (grade ≥3) was higher in women patients receiving ICIs, which requires monitoring more closely.